ChatGPT Ads for life sciences may justify a small pilot for some B2B research tools and services companies, subject to eligibility. The ads appear below ChatGPT’s answers for users on the Free and Go plans, matched to the conversation rather than to keywords. That puts them in front of scientists while they are still working through a research question.
I recently set up a campaign for a European life science tools company. It is too early for results, so this post covers how the platform works, who can advertise, and what I noticed during setup.
Key takeaway: For now, ChatGPT Ads are best treated as a learning exercise: a way to find out which research problems your buyers bring to ChatGPT, provided your offering is eligible and your landing page can continue that conversation.
How do ChatGPT Ads work for life science companies?
A ChatGPT ad is a sponsored placement below a response, labelled and kept separate from the answer. OpenAI states that advertising does not influence what ChatGPT says.
There are no keyword lists. The platform matches ads using:
- the context and intent of the conversation
- your ad copy and landing page
- context hints you write at ad group level
On top of that, you can target by country, platform and custom audiences of at least 25,000 matched users, according to OpenAI’s targeting documentation. Qualifying advertisers can add Negative Phrases, and you can bid per impression, per click, or per click with conversion optimisation.
For a life science advertiser, context hints do most of the qualifying work. Relevance depends on how precisely you describe the research problem your product solves.
Eligibility comes first for biotech and life science advertisers
OpenAI’s ad policy, updated in September 2026, focuses the initial period on consumer categories. Healthcare and medicine advertisers are approved case by case, health services outside the US are generally prohibited, and ads stay out of personal and mental health conversations.
For life science companies, the useful line runs between selling to scientists and making health claims. Our reading of the current rules:
| Offering | ChatGPT Ads outlook | What to watch |
|---|---|---|
| Instruments, reagents and lab software | Workable; our tools campaign was approved automatically | Keep clinical or diagnostic claims out of copy and landing pages |
| CRO, CDMO and research services | Untested by us, likely workable when framed as services to companies | Keep messaging away from patient outcomes |
| Diagnostics and medical testing | Case by case in the US, generally prohibited elsewhere | Expect manual review and possible licensure checks |
| Therapeutics and patient-facing biotech | Heavily restricted | Treatment claims and investigational therapies are disallowed |
Review covers the whole ad, landing page included, so a compliant ad that points to a page full of clinical claims can still be rejected.
Who sees ChatGPT Ads, and is your buyer among them?
Ads only show on the Free and Go plans. Business, Enterprise and other paid workspaces stay ad-free. ChatGPT reaches 1.2 billion people a week, so the free audience is large, but the more useful question is which part of your buying group sits in it.
The people most likely to see an ad are:
- early-career researchers exploring methods, often on personal accounts
- scientists at smaller companies and institutes without enterprise licences
- researchers in markets where paid AI seats are less common
Procurement leads and scientists at companies with enterprise licences are harder to reach. Some US academic labs are moving out of reach too: the Rosalind Academic Plan, launched in October 2026, gives eligible US university labs up to 30 Business Standard seats at no cost for 12 months.
That makes ChatGPT Ads a better fit for the specification stage, when researchers compare methods and tool categories, than for final sign-off.
What I noticed setting up a first ChatGPT Ads campaign
I opened the account from Singapore and targeted 18 European countries with meaningful life science demand. A few notes from setup and the first days:
- Approval: the campaign went through automatically, with no manual review
- Setup: building a campaign is simple, and you can preview the ad as users will see it. ChatGPT can also build it for you, though it asks for many permissions
- Delivery: the campaign delivered at a bid below the platform’s recommendation, even though it flagged that bid as too low
- Reporting: you see clicks, spend, and conversions , but not which prompts triggered an ad
Read these as notes, not findings. This is one campaign, in one category, without conversion data yet. It tells you nothing reliable about cost per lead, and one delivery result does not show that competition is low or that prices will rise.
The case for a ChatGPT Ads pilot is what you learn
Most of the value of an early pilot is information. Because ads are matched to conversations, a test shows which applications, comparisons and problems bring researchers to your site. That feeds into website messaging, LinkedIn and your content plan.
Most of the value of an early pilot is information.
A pilot is also a way into conversations where you are currently absent. Ads run separately from ChatGPT’s answers, so paying does not change what the model says about you. If ChatGPT does not mention your company when researchers ask about your category, an ad is one of the few ways to appear there, while content marketing builds organic visibility over time.
What decides whether a ChatGPT Ads pilot pays off
A ChatGPT ad reaches a researcher mid-question, so the landing page has to continue that conversation. Whether a pilot produces pipeline comes down to:
- a landing page that answers the question the researcher was asking
- an offer that suits someone still in research mode
- conversion tracking in place before spend starts
- reporting that allows for sales cycles measured in months
Each of these depends on your product, your buyer and the evidence you can show. This is the part of biotech advertising where knowing how scientific buyers evaluate a vendor makes the difference.
ChatGPT Ads may justify a small pilot for some research tools and services companies
If you sell instruments, reagents or research services to scientists and your offering clears the eligibility rules, a small, well-tracked pilot is a reasonable way to learn how your buyers use ChatGPT. Diagnostics and therapeutics companies should confirm eligibility before planning anything. I’ll share our results once the campaign has run.
Want help turning ChatGPT Ads clicks into qualified conversations? Biond sets up ChatGPT Ads pilots for life science companies, from eligibility checks and context hints to landing pages and conversion tracking.
Frequently Asked Questions
There are no published cost benchmarks for life science advertisers yet. Costs depend on your field and competition. You can buy per impression, per click or with conversion-optimised bidding, and daily minimums depend on the account currency. Biond’s first life science campaign delivered below the platform’s recommended bid, but one campaign is not a basis for budgeting.
Biond reads OpenAI’s current policy as likely workable for companies selling instruments, reagents and research services to scientists, provided they avoid health claims. Medical testing and diagnostic products are approved case by case in the US, and health services outside the US are generally prohibited. Biotechnology companies promoting therapeutics should expect heavy restrictions.
No. OpenAI states that ads do not influence ChatGPT’s answers, so advertising does not change what the model says about your company. Biond sees ads as most useful while ChatGPT does not yet mention your brand, giving you a position in category conversations while organic visibility is built through content.
No. In Biond’s campaign, reporting showed clicks and spend but not the prompts behind each impression, because conversation content stays private. You shape matching through context hints and can preview how the ad appears. That makes landing page analytics and conversion tracking the main sources of learning from a pilot.
